Categories AlphaGraphs, Earnings, Technology

TWTR Earnings: Twitter Q4 profit, revenue miss estimates

Microblogging platform Twitter (NYSE: TWTR) on Thursday reported weaker-than-expected earnings and revenues for the fourth quarter of 2021. The company’s stock dropped soon after the announcement.

Twitter Q4 2021 earnings infographic

Fourth-quarter earnings, adjusted for special items, declined to $0.33 per share from $0.38 per share last year and came in below the consensus forecast. The company reported a net profit of $181.7 million or $0.21 per share for the December quarter, compared to $222.1 million or $0.27 per share in the year-ago period.

The bottom-line performance was negatively impacted by a sharp increase in operating expenses. Meanwhile, revenues moved up 22% annually to $1.57 billion during the three-month period. Analysts had predicted a faster growth. The average monetizable daily active usage was 217 million.


Read management/analysts’ comments on Twitter’s Q4 earnings


Twitter stock has lost about13% so far this year and is currently trading well below the 52-week average. The shares traded lower in early trading on Thursday soon after the earnings announcement.

Prior Performance

  • Twitter Q3 2021 earnings
  • Twitter Q2 2021 earnings infographic

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top